Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group (Q71775721)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 1995

Language	Label	Description	Also known as
English	Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group	scientific article published on 01 October 1995

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

author name string

A L Robin

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

R Ritch

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

D H Shin

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

B Smythe

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

T Mundorf

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

R P Lehmann

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

language of work or name

0 references

publication date

1 October 1995

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

American Journal of Ophthalmology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

120

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

423-432

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Apraclonidine. A one-week dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Reformulation and drop size of apraclonidine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Prevention of the Rise in Intraocular Pressure Following Neodymium-YAG Posterior Capsulotomy Using Topical 1% Apraclonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Effects of ALO 2145 on intraocular pressure following argon laser trabeculoplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Long-term follow-up of argon laser trabeculoplasty for uncontrolled open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Compliance with ocular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Visual ability and drug regimen: relation to compliance with glaucoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Facilitating patient compliance in glaucoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Effect of apraclonidine in long-term timolol users

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Timolol Plus Maximum-Tolerated Antiglaucoma Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

Additive Effect of 1% Apraclonidine Hydrochloride to Nonselective β-Blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2972655-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9394(14)72655-8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7573299%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71775721&oldid=1746513760"